Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative NeoplasmsAndrew Dunbar, Ross L. Levine, Robert L. Bowman et al.|Cancer Discovery|2024Cited by 30
In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancyRobert L. Bowman, Ross L. Levine, Andrew Dunbar et al.|Cancer Cell|2024Cited by 12
<i>Jak2V617F</i> Reversible Activation Shows an Essential Requirement for Jak2V617F in Myeloproliferative Neoplasms (MPNs)Andrew Dunbar, Ross L. Levine, Franco Izzo et al.|Blood|2022Cited by 4
Jak2 <sup>V617F</sup> Reversible Activation Shows an Essential Requirement for Jak2 <sup>V617F</sup> in Myeloproliferative NeoplasmsAndrew Dunbar, Ross L. Levine, Robert L. Bowman et al.|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 2
Modeling clonal evolution and oncogenic dependency in vivo in the context of hematopoietic transformationRobert L. Bowman, Ross L. Levine, Andrew Dunbar et al.|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 2